388 related articles for article (PubMed ID: 21917607)
1. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
2. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
3. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
Galsky MD; Small AC; Tsao CK; Oh WK
CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
[TBL] [Abstract][Full Text] [Related]
5. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Keizman D; Maimon N; Gottfried M
Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
[TBL] [Abstract][Full Text] [Related]
6. Re: novel therapies for metastatic castrate-resistant prostate cancer.
Sartor O; Parker C
J Natl Cancer Inst; 2012 May; 104(9):717; author reply 717. PubMed ID: 22440684
[No Abstract] [Full Text] [Related]
7. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
8. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
9. Novel and bone-targeted agents for CRPC.
Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
[TBL] [Abstract][Full Text] [Related]
11. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Pal SK; Lewis B; Sartor O
Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
[TBL] [Abstract][Full Text] [Related]
12. A renaissance in the medical treatment of advanced prostate cancer.
Rove KO; Flaig TW
Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
15. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
[TBL] [Abstract][Full Text] [Related]
17. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
18. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
20. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Ketola K; Kallioniemi O; Iljin K
PLoS One; 2012; 7(12):e51470. PubMed ID: 23251544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]